S&P 500   4,244.35 (-0.68%)
DOW   33,334.24 (-0.85%)
QQQ   352.50 (-0.48%)
AAPL   169.56 (-1.40%)
MSFT   310.82 (-0.42%)
META   298.27 (-0.23%)
GOOGL   129.38 (+0.63%)
AMZN   124.81 (-0.93%)
TSLA   235.19 (-3.66%)
NVDA   417.89 (-0.29%)
NIO   8.33 (-0.95%)
BABA   85.51 (-0.47%)
AMD   97.01 (+1.09%)
T   14.85 (-1.13%)
F   12.30 (-1.05%)
MU   67.12 (-1.21%)
CGC   0.86 (-6.73%)
GE   110.69 (+0.69%)
DIS   79.26 (-0.99%)
AMC   7.72 (-2.40%)
PFE   31.93 (-1.45%)
PYPL   56.88 (-3.48%)
NFLX   377.25 (-0.53%)
S&P 500   4,244.35 (-0.68%)
DOW   33,334.24 (-0.85%)
QQQ   352.50 (-0.48%)
AAPL   169.56 (-1.40%)
MSFT   310.82 (-0.42%)
META   298.27 (-0.23%)
GOOGL   129.38 (+0.63%)
AMZN   124.81 (-0.93%)
TSLA   235.19 (-3.66%)
NVDA   417.89 (-0.29%)
NIO   8.33 (-0.95%)
BABA   85.51 (-0.47%)
AMD   97.01 (+1.09%)
T   14.85 (-1.13%)
F   12.30 (-1.05%)
MU   67.12 (-1.21%)
CGC   0.86 (-6.73%)
GE   110.69 (+0.69%)
DIS   79.26 (-0.99%)
AMC   7.72 (-2.40%)
PFE   31.93 (-1.45%)
PYPL   56.88 (-3.48%)
NFLX   377.25 (-0.53%)
S&P 500   4,244.35 (-0.68%)
DOW   33,334.24 (-0.85%)
QQQ   352.50 (-0.48%)
AAPL   169.56 (-1.40%)
MSFT   310.82 (-0.42%)
META   298.27 (-0.23%)
GOOGL   129.38 (+0.63%)
AMZN   124.81 (-0.93%)
TSLA   235.19 (-3.66%)
NVDA   417.89 (-0.29%)
NIO   8.33 (-0.95%)
BABA   85.51 (-0.47%)
AMD   97.01 (+1.09%)
T   14.85 (-1.13%)
F   12.30 (-1.05%)
MU   67.12 (-1.21%)
CGC   0.86 (-6.73%)
GE   110.69 (+0.69%)
DIS   79.26 (-0.99%)
AMC   7.72 (-2.40%)
PFE   31.93 (-1.45%)
PYPL   56.88 (-3.48%)
NFLX   377.25 (-0.53%)
S&P 500   4,244.35 (-0.68%)
DOW   33,334.24 (-0.85%)
QQQ   352.50 (-0.48%)
AAPL   169.56 (-1.40%)
MSFT   310.82 (-0.42%)
META   298.27 (-0.23%)
GOOGL   129.38 (+0.63%)
AMZN   124.81 (-0.93%)
TSLA   235.19 (-3.66%)
NVDA   417.89 (-0.29%)
NIO   8.33 (-0.95%)
BABA   85.51 (-0.47%)
AMD   97.01 (+1.09%)
T   14.85 (-1.13%)
F   12.30 (-1.05%)
MU   67.12 (-1.21%)
CGC   0.86 (-6.73%)
GE   110.69 (+0.69%)
DIS   79.26 (-0.99%)
AMC   7.72 (-2.40%)
PFE   31.93 (-1.45%)
PYPL   56.88 (-3.48%)
NFLX   377.25 (-0.53%)
OTCMKTS:AFFY

Affymax (AFFY) Stock Forecast, Price & News

$0.0042
0.00 (0.00%)
(As of 09/26/2023 ET)
Compare
Today's Range
$0.0042
▼
$0.0042
50-Day Range
N/A
52-Week Range
$0.00
▼
$0.04
Volume
N/A
Average Volume
666 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ProfileChartCompetitorsFinancialsInstitutional OwnershipHeadlinesShort Interest

AFFY stock logo

About Affymax (OTCMKTS:AFFY) Stock

Affymax, Inc. does not have significant operations. Previously, it was developing drugs to enhance the treatment of serious and often life-threatening conditions in the United States. The company was founded in 2001 and is based in New York, New York.

AFFY Price History

AFFY Stock News Headlines

September 25, 2023 | finance.yahoo.com
Jasper Therapeutics Appoints Herb Cross as Chief Financial Officer
September 18, 2023 | markets.businessinsider.com
AnaptysBio Announces Appointment of John Orwin as Chairman of the Board of Directors
September 27, 2023 | Wall Street Fundamentals (Ad)
The "Plug and Play" Model Putting Online Giants to Shame
While e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."
June 7, 2023 | thestreet.com
4 Biotech Stocks Under $5 to Watch
May 15, 2023 | thestreet.com
10 Biotech Stocks on Clinical Trials Watch
January 19, 2023 | bizjournals.com
Why a UCSF vice chancellor is returning to the biotech industry
January 18, 2023 | marketwatch.com
Hinge Bio Expands Senior Management Team to Drive GEM-DIMER(TM) Programs to Clinical Development
January 18, 2023 | nz.finance.yahoo.com
Hinge Bio Expands Senior Management Team to Drive GEM-DIMER™ Programs to Clinical Development
September 27, 2023 | Wall Street Fundamentals (Ad)
The "Plug and Play" Model Putting Online Giants to Shame
While e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."
September 14, 2022 | finanznachrichten.de
Turn Biotechnologies, Inc.: Turn Biotechnologies launches eTurna delivery platform designed specifically to enable nucleic acid therapeutics
August 28, 2022 | reuters.com
AFFY.PK - Affymax, Inc. | Stock Price & Latest News | Reuters
August 25, 2022 | finance.yahoo.com
Frontier Medicines Announces the Appointment of Seasoned Legal Executive Mark Dizon, J.D., as General Counsel
August 3, 2022 | investing.com
Esso Thailand PCL F (ESSOf)
August 3, 2022 | investing.com
Dialog Group Bhd (DIAL)
July 30, 2022 | investing.com
DPS Resources Bhd (DPSS)
April 27, 2022 | marketwatch.com
Renal Disease Treatment Market Size with New Growth Prospect By Top Key Players | Impact of COVID-19 Pandemic
March 27, 2022 | marketwatch.com
Renal Disease Treatment Market Scope with New Growth Prospect By Top Key Players | Impact of COVID-19 Pandemic
September 2, 2021 | ca.finance.yahoo.com
Arcutis Announces Appointment of Keith Leonard to Board of Directors
April 28, 2021 | ca.finance.yahoo.com
Dr. Mike Holfinger Joins Alladapt as Chief Technical Officer
January 20, 2021 | apnews.com
T-knife Announces Appointment of Thomas M. Soloway as Chief Executive Officer and Camille A.
December 29, 2020 | marketwatch.com
PEGylated Protein Therapeutics Market Global Trends, Market Share, Industry Size, Growth, Opportunities and Market Forecast 2020 to 2027
December 5, 2020 | apnews.com
Pipeline Therapeutics Appoints Julie Iwashita as Vice President of Clinical Operations
August 16, 2020 | markets.businessinsider.com
Affymax IncShs - Profile
July 23, 2020 | www.marketwatch.com
Affymax Inc.
March 8, 2020 | www.bloomberg.com
Pomerantz Law Firm Announces Summary Notice of Pendency and Proposed Settlement of Affymax, Inc. Class Action and Settlement
December 4, 2019 | finance.yahoo.com
RubrYc Therapeutics Announces formation of its Scientific Advisory Board
July 11, 2019 | www.marketwatch.com
Atreca Further Strengthens Management Team with Appointment of Lisa Decker as Chief Business Officer and Courtney Phillips as General Counsel
See More Headlines
Receive AFFY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Affymax and its competitors with MarketBeat's FREE daily newsletter.

AFFY Company Calendar

Today
9/27/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
OTCMKTS:AFFY
CUSIP
00826A10
CIK
1158223
Web
www.affymax.com
Phone
(650) 812-8700
Fax
650-424-0832
Employees
2
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
5.70
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Mr. Mark G. Thompson (Age 61)
    CFO & Sec.
    Comp: $97.49k
  • Mr. Jonathan M. Couchman (Age 53)
    CEO, Pres & Director
  • Dr. Tracy J. Dunn Ph.D. (Age 60)
    J.D., VP of Intellectual Property & Legal Affairs

Key Competitors

View All Competitors













AFFY Stock - Frequently Asked Questions

How have AFFY shares performed in 2023?

Affymax's stock was trading at $0.0040 on January 1st, 2023. Since then, AFFY shares have increased by 5.0% and is now trading at $0.0042.
View the best growth stocks for 2023 here.

What other stocks do shareholders of Affymax own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Affymax investors own include Golden Peak Minerals Inc.. (GRM), (MCPIQ) (MCPIQ), Bank of America (BAC), Boeing (BA), American Express (AXP), Aurinia Pharmaceuticals (AUPH), Actinium Pharmaceuticals (ATNM), Advanced Micro Devices (AMD), Alnylam Pharmaceuticals (ALNY) and Achaogen (AKAO).

What is Affymax's stock symbol?

Affymax trades on the OTCMKTS under the ticker symbol "AFFY."

How do I buy shares of Affymax?

Shares of AFFY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Affymax's stock price today?

One share of AFFY stock can currently be purchased for approximately $0.00.

How can I contact Affymax?

Affymax's mailing address is 19200 STEVENS CREEK BOULEVARD SUITE 240, CUPERTINO CA, 95014. The official website for the company is www.affymax.com. The biopharmaceutical company can be reached via phone at (650) 812-8700, via email at investors@affymax.com, or via fax at 650-424-0832.

This page (OTCMKTS:AFFY) was last updated on 9/27/2023 by MarketBeat.com Staff

My Account -